tbuckley/cabot-search huggingface dataset:
Targeting the correct target in HCC
Authors: Carmen Berasain, André Lechel
Journal: Gut (2017)

Hepatocellular carcinoma (HCC) is the most frequent liver cancer and one of the most common causes of cancer-related death. The rates of incidence and mortality of HCC are increasing worldwide. Unfortunately, both figures are very similar mainly due to the longer survival of patients with cirrhosis, the aggressiveness of HCC and the lack of efficient therapies.1 ,2 Since 2008, sorafenib, a multikinase (BRAF/vascular endothelial growth factor receptor/platelet-derived growth factor receptor) inhibitor is the only approved systemic therapy for advanced HCC. Sorafenib offers modest survival benefit, and recently some concerns about its cost-effectiveness have been raised.3 In the last years, many other molecular targeted agents have been tested for the treatment of HCC in different clinical trials with negative results.2 ,4 

The limited efficacy of sorafenib and the rest of the molecular therapies assayed against HCC can be linked to the existence of primary and the emergence of acquired drug resistance mechanisms.5 However, it is becoming evident that the main reason for the failure of targeted therapies in HCC is their administration to an unselected population of patients due to the lack of specific biomarkers.

Precision medicine is characterised by targeting a specific molecular alteration, which in the case of cancer is supposed to dominate the malignant phenotype. The primary success of a targeted therapy for a particular tumour will rely mainly on a correct process of identification and …
Feasibility and Efficacy of Peripheral Blood Progenitor Cell Mobilisation with Pegfilgrastim for Allogeneic Stem Cell Transplantation.
Authors: Frank Kroschinsky, Kristina Hoelig, Rainer Ordemann, Astrid Haack, Kirsten Poppe-Thiede, Matthias Blechschmidt, Gabi Rall, Martin Bornhaeuser, Eberhard Schleyer, Claudia Rutt, Gerhard Ehninger
Journal: Blood (2004)
Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Authors: Xavier Poiré, Myriam Labopin, Johan Maertens, Ibrahim Yakoub-Agha, Didier Blaise, Norbert Ifrah, Gérard Socié, Tobias Gedde-Dhal, Nicolaas Schaap, Jan J. Cornelissen, Stéphane Vigouroux, Jaime Sanz, Lucienne Michaux, Jordi Esteve, Mohamad Mohty, Arnon Nagler
Journal: Journal of Hematology & Oncology (2017)

Acute myeloid leukaemia (AML) with 17p abnormalities (abn(17p)) carries a very poor prognosis due to high refractoriness to conventional chemotherapy, and allogeneic stem cell transplantation (allo-SCT) appears as the only potential curative option. To address outcomes after allo-SCT in patients with abn(17p), we retrospectively analysed de novo or secondary AML undergoing SCT between 2000 and 2013 from the EBMT registry. One hundred thirty-nine patients with confirmed abn(17p) have been selected. At the time of transplant, one hundred twenty-five were in first remission (CR1). Median age was 54 years old. Abn(17p) was associated with a monosomal karyotype in 83% of patients, complex karyotype in 91%, monosomy 5 or 5q deletion (-5/5q-) in 55%, monosomy 7 (-7) in 39% and both -5/5q and -7 in 27%. Seventy-three patients (59%) had a reduced-intensity conditioning regimen. The 2-year overall survival (OS) and leukaemia-free survival (LFS) were 28 and 24%, respectively. The 2-year non-relapse mortality (NRM) was 15%, and 2-year relapse incidence (RI) was 61%. The cumulative incidence of grade II to IV acute graft-versus-host disease (GvHD) was 24% and that of chronic GvHD was 21%. In multivariate analysis, the presence of a -5/5q- in addition to abn(17p) was significantly and independently associated with worse OS, LFS and higher RI. Age and donor types did not correlate with outcome. Conditioning intensity was not statistically associated with OS, LFS and NRM when adjusted for patients’ age. In contrast to the dismal prognosis reported for AML patients harbouring abn(17p) undergoing conventional chemotherapy, allogeneic SCT provides responses in about 25% of those patients transplanted in CR1.
Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study
Authors: Jean-François Etard, Mamadou Saliou Sow, Sandrine Leroy, Abdoulaye Touré, Bernard Taverne, Alpha Kabinet Keita, Philippe Msellati, N'Fally Magassouba, Sylvain Baize, Hervé Raoul, Suzanne Izard, Cécé Kpamou, Laura March, Ibrahima Savane, Moumié Barry, Eric Delaporte, Ahidjo Ayouba, Sylvain Baize, Kaba Bangoura, Alimou Barry, Moumié Barry, Mamoudou Cissé, Mohammed Cissé, Eric Delaporte, Jean-François Delfraissy, Christelle Delmas, Alice Desclaux, Saliou Bella Diallo, Mamadou Safiatou Diallo, Mariama Sadjo Diallo, Jean François Étard, Cécile Etienne, Ousmane Faye, Ibrahima Fofana, Bruno Granouillac, Esther Hereth Hébert, Suzanne Izard, Djenaba Kassé, Alpha Kabinet Keita, Sakoba Keita, Lamine Koivogui, Cécé Kpamou, Christine Lacarabaratz, Sandrine Leroy, Claire Levy Marchal, Yves Levy, N'Fally Magassouba, Laura March, Vincent Mendiboure, Philippe Msellati, Harissatou Niane, Martine Peeters, Yves-Marie Pers, Hervé Raoul, Sidi Lamine Sacko, Ibrahima Savané, Mamadou Saliou Sow, Bernard Taverne, Abdoulaye Touré, Fodé Amara Traoré, Falaye Traoré, Yamoussa Youla, Yazdan Yazdanpanah
Journal: The Lancet Infectious Diseases (2017)
Role of Pyridoxal 5′-Phosphate at the Titanium Implant Interface In Vivo: Increased Hemophilicity, Inactive Platelet Adhesion, and Osteointegration
Authors: Jung Seung Lee, Kyuri Kim, Joseph P. Park, Seung‐Woo Cho, Haeshin Lee
Journal: Advanced Healthcare Materials (2017)

Titanium is the most biocompatible inorganic biomaterial with a long history of use in orthopedic and dental implants. However, promoting rapid and effective bone formation and integration onto etched, rough TiO2 surfaces has been a challenging topic. Here, 21 commercially available molecules are examined that met the following criteria: (1) contain phosphonic acid for stable immobilization onto TiO2 surfaces and (2) have a molecular weight less than 500 Da for negligible coating thickness. Of these molecules, the surface immobilization of pyridoxal 5'-phosphate (PLP), an active form of vitamin B6 , dramatically increases the hemophilic property of the surface and accelerated osteointegration in vivo. Analysis shows that PLP promotes surface binding of serum albumin and other plasma proteins by Schiff-base formations via its aldehyde group, providing a platform suitable for osteoblast adhesion. PLP also retards blood coagulation more than the widely used citric acid at the TiO2 surface. As PLP is capable of maintaining an inactivated status of surface-adsorbed platelets, delayed coagulation at the implant-blood interface allows for sufficient supply of growth factors from blood plasma and migration of osteoblasts. The results suggest that PLP can be widely applicable as a biocompatible, effective coating compound to promote osteointegration of titanium-based implants.
Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia
Authors: Luciano J Costa, Suzanne Fanning, Joseph Stephenson, Lawrence Afrin, Tricia Bentz, Shanta Salzer, Rachel Whirley, Carlyn Sander, Robert K Stuart
Journal: Blood (2012)
Two Mutations (1717 T〉C, GP IX;124del145, GPIb beta) Occur Frequently among Patients with Bernard Soulier Syndrome in India.
Authors: Rintu Rebecca Jacob, G. Jayandharan, Auro Viswabandya, Shoma Baidya, Sukesh C. Nair, Biju George, Vikram Mathews, Mammen Chandy, Alok Srivastava
Journal: Blood (2006)
Coincidence of Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) in One Patient: An Exceptional or Common Event? Summary of 4 Cases at a Single Center.
Authors: Justyna Rawluk, Percy Schröttner, Ullrich Denz, Dietmar Pfeifer, Milena Pantic, Hendrik Veelken, Monika Engelhardt
Journal: Blood (2006)
Imatinib as Salvage Therapy for Patients with Refractory cGVHD: the Interim Analysis of the Prospective GITMO* Multicenter Study*Gruppo Italiano Trapianto Di Midollo Osseo.
Authors: Attilio Olivieri, Michele Cimminiello, Paolo Corradini, Pasquale Iacopino, Amedea Donelli, Nicola Mordini, Carmine Selleri, Vincenzo Pavone, Renato Fanin, Franco Locatelli, Andrea Bacigalupo, Alberto Bosi
Journal: Blood (2009)
Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis
Authors: Elizabeth A. David, Megan E. Daly, Chin-Shang Li, Chi-Lu Chiu, David T. Cooke, Lisa M. Brown, Joy Melnikow, Karen Kelly, Robert J. Canter
Journal: Journal of Thoracic Oncology (2017)
Mesenchymal Stromal Precursor Cells from the Bone Marrow of Acute Myeloid and Lymphoid Leukemia Patients: Characteristics in Newly Diagnosed, before and after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Irina N. Shipounova, Natalia Petinati, Alexey Bigildeev, Nina I. Drize, Tamara Sorokina, Larisa A Kuzmina, Elena N. Parovichnikova, Valeri G. Savchenko
Journal: Blood (2014)
Impact of Imatinib Dose Escalation in Chronic Myeloid Leukemia Patients in Chronic Phase with Sub-Optimal Response or Failure with Imatinib 400 Mg.
Authors: Katia BB Pagnano, Marcia T Delamain, Eliana C.M. Miranda, Vagner O Duarte, Brunna Eulálio Alves, Carmino Antonio De Souza, Irene Lorand-Metze
Journal: Blood (2009)
Patients with Monosomal Karyotype in Acute Myeloid Leukemia Is Prognostically Worse Than with Complex Karyotype
Authors: Liu Xiaoli, Xu Na, DU Qingfeng, Xu Dan, Meng Fanyi, Xu Lulu, Zhang Jinfang, Huang Bintao, Luo Xujing
Journal: Blood (2011)
Abnormal Serum Free Light Chain Ratios Are Associated with Earlier Time to First Treatment and Poor Survival in Patients with Chronic Lymphocytic Leukaemia
Authors: Guy Pratt, Graham Mead, Supratik Basu, Abe Jacobs, Roger Holder, Chris Fegan, Chris Pepper, Arthur R. Bradwell, David Oscier, Stephen Harding
Journal: Blood (2008)
Performance of microscopic observation drug susceptibility for the rapid diagnosis of tuberculosis and detection of drug resistance in Bamako, Mali
Authors: M. Sanogo, B. Kone, B. Diarra, M. Maiga, B. Baya, A.M. Somboro, Y.S. Sarro, A.C.G. Togo, B.P.P. Dembele, D. Goita, A. Kone, O. M'Baye, N. Coulibaly, S. Diabate, B. Traore, M.H. Diallo, Y.I. Coulibaly, P. Saleeb, M. Belson, S. Orsega, S. Siddiqui, M.A. Polis, S. Dao, R.L. Murphy, S. Diallo
Journal: Clinical Microbiology and Infection (2017)
The Kinetic of Reduction of Minimal Residual Disease Impacts on duration of Response snd Survival of Patients with Acute Myeloid Leukemia.
Authors: Francesco Buccisano, Luca Maurillo, Giovanni Del Poeta, Anna Tamburini, Maria Christina Cox, Maria Ilaria Del Principe, Maria Irno Consalvo, Carla Mazzone, Benedetta Neri, Licia Ottaviani, Francesco Lo Coco, Sergio Amadori, Adriano Venditti
Journal: Blood (2004)
406P The association between ICD-10 criteria for cancer-related fatigue and symptom distress among cancer patients during treatment in different geographic areas in Taiwan
Authors: Y.-J. Chou, S.C. Shun, R.-K. Hsieh, M.-Y. Lee, W.T. Huang, K.H. Yeh, C.S. Chang, S.C. Lin
Journal: Annals of Oncology (2015)
Impact of Conditioning on the Outcome of Allografting in Myelofibrosis with Myeloid Metaplasia: Better Survival with Reduced Intensity Approach in Patients ≥50 Years.
Authors: Vikas Gupta, Nicolaus Kroger, Johan Aschan, Brian Leber, Christopher Dalley, Mitchell Sabloff, Jeffrey H. Lipton, Hans Messner, Wei Xu, Mats Brune
Journal: Blood (2007)
Proteasome Inhibitor Bortezomib Can Inhibit Bone Marrow Fibrosis Development in a Murine Model of Myelofibrosis.
Authors: Orianne Wagner-Ballon, Thomas Gastinne, Micheline Tulliez, Catherine Lacout, Didier Pisani, Hedia Chagraoui, Jean-Luc Villeval, William Vainchenker, Stephane Giraudier
Journal: Blood (2005)
Tau Pathology Induces Excitatory Neuron Loss, Grid Cell Dysfunction, and Spatial Memory Deficits Reminiscent of Early Alzheimer’s Disease
Authors: Hongjun Fu, Gustavo A. Rodriguez, Mathieu Herman, Sheina Emrani, Eden Nahmani, Geoffrey Barrett, Helen Y. Figueroa, Eliana Goldberg, S. Abid Hussaini, Karen E. Duff
Journal: Neuron (2017)
Xenografts of Pediatric Acute Lymphoblastic Leukemia Retain the Gene Expression Pattern From the Diagnostic Material They Originated From Over Serial Passages.
Authors: Manon Queudeville, Elena Vendramini, Marco Giordan, Sarah M. Eckhoff, Giuseppe Basso, Klaus-Michael Debatin, Truus Te Kronnie, Lueder H. Meyer
Journal: Blood (2009)
Down Regulation of Hepcidin and Haemojuvelin Expression in the Hepatocyte Cell-Line HepG2 Induced by Thalassaemic Sera.
Authors: Orly Weizer-Stern, Konstantin Adamsky, Ninette Amariglio, Carina Levin, Ariel Koren, William Breuer, Eliezer Rachmilewitz, Sara Gardenghi, Stefano Rivella, Yoav Cabantchik, Gideon Rechavi
Journal: Blood (2006)
Enzyme efficiency but not thermostability drives cefotaxime resistance evolution in TEM-1 β-lactamase
Authors: Jennifer Knies, Fei Cai, Daniel M. Weinreich
Journal: Molecular Biology and Evolution (2017)

A leading intellectual challenge in evolutionary genetics is to identify the specific phenotypes that drive adaptation. Enzymes offer a particularly promising opportunity to pursue this question, because many enzymes' contributions to organismal fitness depend on a comparatively small number of experimentally accessible properties. Moreover, on first principles the demands of enzyme thermostability stand in opposition to the demands of catalytic activity. This observation, coupled with the fact that enzymes are only marginally thermostable, motivates the widely held hypothesis that mutations conferring functional improvement require compensatory mutations to restore thermostability. Here, we explicitly test this hypothesis for the first time, using four missense mutations in TEM-1 β-lactamase that jointly increase cefotaxime Minimum Inhibitory Concentration (MIC) ∼1500-fold. First, we report enzymatic efficiency (kcat/KM) and thermostability (Tm, and thence ΔG of folding) for all combinations of these mutations. Next, we fit a quantitative model that predicts MIC as a function of kcat/KM and ΔG. While kcat/KM explains ∼54% of the variance in cefotaxime MIC (∼92% after log transformation), ΔG does not improve explanatory power of the model. We also find that cefotaxime MIC rises more slowly in kcat/KM than predicted. Several explanations for these discrepancies are suggested. Finally, we demonstrate substantial sign epistasis in MIC and kcat/KM, and antagonistic pleiotropy between phenotypes, in spite of near numerical additivity in the system. Thus constraints on selectively accessible trajectories, as well as limitations in our ability to explain such constraints in terms of underlying mechanisms are observed in a comparatively "well-behaved" system.
Design of an Ongoing Phase I/II Open-Label, Dose-Escalation Trial Using the Oral Chelator Deferasirox To Treat Iron Overload in HFE-Related Hereditary Hemochromatosis (HH).
Authors: A. Pietrangelo, P. Brissot, H. Bonkovsky, C. Niederau, L. Rojkjaer, R. Weitzman, J. Bodner, S. Bailey, Pradyumna D. Phatak
Journal: Blood (2007)
Results of Treatment of Severe Aplastic Anaemia in Children Using Rabbit Antithymocyte Globulin(r-ATG),
Authors: Malgorzata Salamonowicz, Katarzyna Pawelec, Michal Matysiak, Jerzy Kowalczyk, Walentyna Balwierz, Ewa Zaleska-Czepko, Alicja Chybicka, Krzysztof Szmyd, Tomasz Szczepanski, Halina Bubala, Mariusz Wysocki, Andrzej Kurylak, Jacek Wachowiak, Dawid Szpecht, Wojciech Mlynarski, Monika Bulas, Maryna Krawczuk-Rybak, Anna Panasiuk, Elzbieta Leszczynska, Tomasz Urasinski, Jaroslaw Peregud-Pogorzelski, Anna Balcerska, Barbara Kaczorowska-Hac
Journal: Blood (2011)
Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance
Authors: Abigail L Manson, Keira A Cohen, Thomas Abeel, Christopher A Desjardins, Derek T Armstrong, Clifton E Barry, Jeannette Brand, Sinéad B Chapman, Sang-Nae Cho, Andrei Gabrielian, James Gomez, Andreea M Jodals, Moses Joloba, Pontus Jureen, Jong Seok Lee, Lesibana Malinga, Mamoudou Maiga, Dale Nordenberg, Ecaterina Noroc, Elena Romancenco, Alex Salazar, Willy Ssengooba, A A Velayati, Kathryn Winglee, Aksana Zalutskaya, Laura E Via, Gail H Cassell, Susan E Dorman, Jerrold Ellner, Parissa Farnia, James E Galagan, Alex Rosenthal, Valeriu Crudu, Daniela Homorodean, Po-Ren Hsueh, Sujatha Narayanan, Alexander S Pym, Alena Skrahina, Soumya Swaminathan, Martie Van der Walt, David Alland, William R Bishai, Ted Cohen, Sven Hoffner, Bruce W Birren, Ashlee M Earl
Journal: Nature Genetics (2017)
Risk Stratification of Pediatric Patients With Neuroblastoma Using Volumetric Parameters of 18F-FDG and 18F-DOPA PET/CT
Authors: Chia-Ju Liu, Meng-Yao Lu, Yen-Lin Liu, Chi-Lun Ko, Kuan-Yin Ko, Kai-Yuan Tzen, Hsiu-Hao Chang, Yung-Li Yang, Shiann-Tarng Jou, Wen-Ming Hsu, Ruoh-Fang Yen
Journal: Clinical Nuclear Medicine (2017)

This study determined the prognostic value of volumetric parameters derived from pretreatment F-FDG and F-DOPA PET/CT of neuroblastoma and their correlation with clinical and histopathologic features.A total of 25 children with neuroblastoma underwent pretreatment F-FDG and F-DOPA PET/CT within 4 weeks. The SUVmax of primary tumors on F-FDG and F-DOPA PET were recorded as SUVFDG and SUVDOPA, respectively. For volumetric parameters of primary tumors, 40% of SUVmax was used to generate volume of interest. If the 40% of SUVmax was below 2.5, an SUV threshold of 2.5 was used instead. Metabolic tumor volume (MTV), total lesion glycolysis (TLG), dopaminergic tumor volume (DTV), and total lesion F-DOPA activity (TLDA) were recorded as F-FDG and F-DOPA volumetric parameters. All indices were compared between groups distinguished by survival status and clinical features, including bone marrow involvement, lymph node metastasis, amplification of the MYCN oncogene, invasive features on anatomic images, and risk categories. The Kaplan-Meier method and log-rank test were used to compare the survival curves between groups.The median follow-up period was 28.2 months. Nonsurvivors (20%) tended to have lower SUVDOPA, DTV, and TLDA (P ≤ 0.05), and higher SUVFDG, MTV, and TLG (all P < 0.05). Lower F-DOPA uptake is associated with bone marrow and lymph node metastases (all P < 0.05). Higher F-FDG uptake is associated with MYCN amplification (all P < 0.05) and anatomic invasive features of tumors such as vascular encasement or adjacent organ invasion (TLG, P = 0.05). Only volumetric indices (DTV, TLDA, MTV, and TLG) significantly differed among risk groups (all P < 0.05).Pretherapeutic F-DOPA and F-FDG PET provided complementary information, and both can be served for risk stratification. Volumetric indices of F-DOPA and F-FDG PET correlate more highly with risk grouping.
Peripherally Inserted Central Catheters (PICCs) Can Be Successfully Utilized in Haematological Patients: Efficacy of an Educational Program.
Authors: Alessandra Malato, Andrea Luppino, Raffaele Pipitone, Maria Grazia Donà, Francesco Acquaviva, Raimondo Di Bella, Rosanna Scimè, Francesco Fabbiano
Journal: Blood (2012)
The Use of Clofarabine and Cytarabine Combination (CLARA) As Salvage Therapy for Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
Authors: Anskar Y.H. Leung, Eric Tse, Herman S.Y. Liu, Joycelyn Sim, Bonnie C.S. Kho, Sze-Fai Yip, Harold K.K. Lee, Yok Lam Kwong
Journal: Blood (2012)
18f-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (PET/CT) for Assessment of Bone Marrow Metabolism in Patients with Myelofibrosis
Authors: Thorsten Derlin, Haefaa Alchalby, Peter Bannas, Simon Veldhoen, Guntram Büsche, Ioanna N Triviai, Frank Bengel, Nicolaus Kröger
Journal: Blood (2014)
In Vitro Study of the Function of Dendritic Cells on Stimulating T Lymphocytes Proliferation in Severe Aplastic Anemia
Authors: Zonghong Shao, Jun Wang, Rong Fu, Lijuan Li, Hui Liu, Wen Qu, Erbao Rua, Yong Liang, Hong Liu, Yuhong Wu, Guojin Wang, Jia Song, Huaquan Wang, Limin Xing, Jing Guan, Xiaoming Wang
Journal: Blood (2008)
A Large Majority of Donor NeoR-Expressing Gene Modified T-Cells Circulating More Than 9 Years after Infusion with allo-BMT, and Capable of Being In-Vitro Expanded and Cloned, Contain a Large Deletion of the HS-tk Gene and Arise from One T-Cell Clone in Each Patient.
Authors: Marina Deschamps, Patricia Mercier, Céline Pagneux, Jean-Marie Certoux, Eric Deconinck, Eric Robinet, Pierre Tiberghien, Christophe Ferrand
Journal: Blood (2006)
Effects of Prophylactic Defibrotide for Veno-Occlusive Disease in Hematopoietic Stem Cell Transplantation
Authors: Meerim Park, Hyeon Jin Park, Hyeon-Seok Eom, Jeong A Park, Yeon Jung Lim, Jong Hyung Yoon, Hye Won Lee, Tak Yun, Byung-Kiu Park
Journal: Blood (2011)
Superior Acute Myeloid Leukemia-Specific T Cell Responses Using Dendritic Cells Pulsed with Apoptotic Bodies, vs.Tumor Lysates or mRNA.
Authors: Dongxia Xing, William K. Decker, Sufang Li, Richard E. Champlin, John D. MacMannis, Krishna V. Komanduri, Marcos de Lima, Elizabeth J. Shpall
Journal: Blood (2005)
Comparison of Autologous and Allogeneic Transplantation As Therapy of First Relapse in Patients with Multiple Myeloma - Long-Term Follow up Analysis,
Authors: Ute Hegenbart, Stefan O Schonland, Axel Benner, Christina Wunder, Thomas M. Moehler, Jens Hillengass, Martin Görner, Jana Schlenzka, Kai Neben, Peter Dreger, Anthony D. Ho, Hartmut Goldschmidt
Journal: Blood (2011)
The Pattern of KIR Ligands in Adult Patients with AML Is Associated with Various Post-Transplant Complications, Including GvHD after HLA-Matched Sibling or Unrelated Donor Transplantation
Authors: Heeje Kim, Woo-Sung Min, Byung-Sik Cho, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Jung-Lim Lee, Jong-Wook Lee, Chun-Choo Kim
Journal: Blood (2008)
Successful Umbilical Cord Blood Transplants in Adults Who Received a Nucleated Cell Dose ≥ 1 X 107 Cells/kg Processed by a Post-Thaw Non-Wash Procedure.
Authors: Patrick Stiff, Michael Shane, Tulio Rodriguez, Jared Klein, Mala Parthasarathy, John Norton, Amir Toor
Journal: Blood (2005)
Results of a Phase I/II Randomized Immunotherapy Trial Testing Adoptive Transfer of Co-Stimulated Autologous T Cells and Pneumococcal Conjugate Vaccine (PCV) Immunization after Autotransplantation for Myeloma (MM).
Authors: Alan Cross, Aaron P. Rapoport, Bruce L. Levine, Edward A. Stadtmauer, Carl H. June, Dean Mann, Carl Frasch, Christian Lynch, Ashraf Badros, Lisa Chrisley, Julio Cotte, Rebecca Mair, Joanne Hinkle, Lei Zhang, Robert Edelman
Journal: Blood (2004)